OMass
Genentech (Roche) Signs $420 Million Deal With OMass Therapeutics for Preclinical IBD Program
Genentech; Roche; OMass Therapeutics; inflammatory bowel disease (IBD); preclinical program; biotech partnership; OdyssION platform; small molecule therapy; drug discovery; milestone payments